T
he Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) is a nationally endorsed guideline process, targeting primary care health care practitioners. The C-CHANGE guideline is a composite of nine of Canada's cardiovascular-focused clinical practice guidelines (Table 1) , chosen to meet primary care needs, including managing patients with multiple comorbidities, and since 2011 has been part of Canada's robust and successful cardiovascular guideline efforts. 8, 9 Ninety percent of Canadians still have suboptimal cardiovascular health from multiple cardiovascular risk factors, higher rates of obesity and diabetes, 15 and suboptimal control of hypertension, dyslipidemia and blood glucose. 16 The compilation of the best available evidence into a nationally recognized and valuable set of best practices provides a common starting point for local and regional implementation strategies to achieve target control rates, including the enabling of interprofessional care. Putting evidence-based best practices into the hands of primary care health care practitioners may accelerate improved outcomes in Canada, but the main challenge is how best to implement the new recommendations, with efforts cognizant of local context and tailored to the needs of regional and local populations. The goal of the C-CHANGE process is for all Canadian health care practitioners to have easy access to a comprehensive and usable set of harmonized guidelines.
The third cycle of the C-CHANGE process was initiated as a result of many updates to the participating guidelines, including a complete update of the Canadian Association of Cardiovascular Prevention and Rehabilitation and Obesity Canada guidelines and the addition of guidelines on heart failure. In each C-CHANGE cycle, efforts are made to improve and harmonize guideline development with all partner organizations so that each guideline scores highly on the AGREE II (Appraisal of Guidelines for Research & Evaluation II) Instrument, which evaluates the process of guideline development and quality of reporting.
Scope
This guideline is directed to primary health care providers caring for Canadian adults who have or are at risk of developing chronic cardiovascular diseases, including hypertension, diabetes, dyslipidemia, heart failure and stroke, and the risk factors for these conditions, including smoking, obesity and physical inactivity. The purpose of the C-CHANGE guideline is to bring together a comprehensive set of recommendations drawn from the nine participating guideline groups applicable to the care of people with multiple comorbidities. The aim is also to do this with sufficient rigour that health care practitioners and patients have confidence in the C-CHANGE process, as well as in the guidelines from the nine participating groups.
Methods

Guideline panel composition
This C-CHANGE guideline update was developed by a volunteer guideline panel, which is a scientific committee that reflects the authors of this paper and draws representation from each of the guideline partner organizations involved in the C-CHANGE process, along with primary care physicians with expertise in guideline dissemination (Appendix 2, available at www.cmaj.ca/ lookup/suppl/doi:10.1503/cmaj.180194/-/DC1). C-CHANGE works with each of the guideline groups to support quality improvement in guideline development in the domains outlined by the AGREE II Instrument. 17 The C-CHANGE process uses a modified Delphi method to select a subset of all of the guideline partners' recommendations that are appropriate for a primary care setting. 8 Appendix 3, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.180194/-/DC1, outlines the process and timeline undertaken for the 2018 C-CHANGE update.
Guideline development
In the fall of 2016, the C-CHANGE guideline groups were contacted and agreed to participate in a consensus conference in June of 2017, as there were sufficient updates in the individual guideline groups to justify a C-CHANGE update and there was also the possibility that the heart failure guidelines would be ready for this C-CHANGE cycle (Appendix 3). Individual recommendations are chosen from each guideline group for inclusion in C-CHANGE to meet the needs of patients with the most common clusters of comorbidities, as hypertension, diabetes and dyslipidemia cluster together. 18 The Canadian Cardiovascular Society's heart failure group had been working with C-CHANGE for the last three years to update its guideline process and became the ninth major guidelines group to join the C-CHANGE collaboration. The addition of the heart failure recommendations had to wait until they were published in October 2017. From the 2017 comprehensive update of the Canadian Cardiovascular Society heart failure guideline, eight specific recommendations were chosen, using the modified Delphi process, as being the most appropriate for This independent expert body in guideline review conducted a review and identified 6 guidelines that met criteria for quality and applicability to local context. Summary statements were extracted and assigned a grade of recommendation and level of evidence by a second expert panel. 2 The ADAPTE framework was used to guide the contextual adaptation (www.g-i-n.net/working-groups/adaptation/history); AGREE II was used to rate and select appropriate guidelines.
Canadian Cardiovascular Society -guideline for the management of heart failure 3 
GRADE
Canadian Cardiovascular Society -guideline for the management of dyslipidemia 4 
GRADE Canadian Association of Cardiovascular Prevention and Rehabilitation
Hypertension Canada process (www.hypertension.ca) Canadian Society for Exercise Physiology 5 The Canadian Society for Exercise Physiology guideline steering committee used the AMSTAR tool (www.amstar.ca/docs/AMSTARguideline.pdf) to assess the methodological quality of the systematic reviews; conclusions from the reviews were assigned a level of evidence [6] [7] [8] [9] based on quality of the study, and level of evidence was used to develop appropriate wording for the guideline. 
GRADE
Heart and Stroke Foundation 13 
Note: AGREE II = Appraisal of Guidelines for Research & Evaluation II, AMSTAR = Assessment of Multiple Systematic Reviews, C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, GRADE = the Grading of Recommendations, Assessment, Development and Evaluation framework. 14 primary care health care practitioners, and were added to the C-CHANGE guideline. 3 Agreements were established between the guideline groups about timing of publication of C-CHANGE and each individual group.
C-CHANGE ensures the quality of each partner guideline group using the AGREE II Instrument 17 to assess the quality and reporting of the guideline. C-CHANGE performs an appraisal using AGREE II for the guideline groups; the appraisals can be found online (www.cchangeguidelines.com). For more information on using AGREE II and the quality improvement process, see Appendix 4, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.180194/-/DC1 (Quality Improvement in C-CHANGE Guideline).
Management of competing interests
Funding for the C-CHANGE consensus conference and administrative support came from the Canadian Institutes of Health Research and in-kind support from the scientific and professional volunteers engaged in the process.
Seven of the nine guideline groups require their guideline panel members to disclose any potential competing interests by the time of their consensus conference, or early in the development process. Members with direct competing interests are asked to abstain from voting in the areas in which they have the conflict.
In the other two guideline groups, the Canadian Cardiovascular Society and the Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment, mitigation of competing interests and prevention of bias are approached by requiring a majority of their panel members in each guideline subgroup to have no relationships with industry; competing interests are declared early in the development process to ensure the required panel composition. In these two guideline subgroups, expert opinion from committee members with competing interests are welcomed at the consensus conference with the recognition of their potential bias. Experts in critical appraisal who have no competing interests make up the review committees to ensure the evidence has been assessed appropriately, and to provide a respected voice at the consensus discussions and debates, ensuring recommendations are aligned with the evidence. These experts in critical appraisal are part of the individual guideline groups and, for Diabetes Canada and Hypertension Canada, led the guideline development process (DS and DR, respectively). As leads of their respective processes, these two critical appraisal experts were also part of the C-CHANGE guideline process.
Recommendations
The 2018 update to the C-CHANGE guideline includes a total of 77 recommendations originating from the nine partner guideline groups, including 52 recommendations that have been newly added or updated (Tables 2-8 ). The ninth guideline (Canadian Cardiovascular Society Guidelines for the Management of Heart Failure) 7 was added to C-CHANGE this year, with eight heart failure recommendations. The complete list of 2018 C-CHANGE recommendations is available in Appendix 1, with a full discussion of the evidence supporting each recommendation.
In the recommendations, it was important to keep the focus on multifaceted optimal medical care, which remains a goal for people with diabetes and, by extension, those at higher risk of cardiovascular disease (Box 2). Management of multifaceted care in the ambulatory care setting is facilitated with an interprofessional team approach. 
Heart failure
We suggest daily morning weight should be monitored in patients with heart failure, with fluid retention or congestion that is not easily controlled with diuretics, or in patients with significant renal dysfunction.
HF †
Note: C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, HF = Canadian Cardiovascular Society -Heart Failure. *All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence). †Based on consensus opinion.
Box 1: Strength of recommendations and quality of evidence
The individual guideline groups have a rigorous methodology to assess the quality of evidence for the development of guidelines, and these are listed in Table 1 . There are two dimensions describing each of the recommendations: the first is the strength of the recommendation, and the second the quality of the evidence supporting it, based on quality and certainty. All Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) recommendations are "should do" or "should not do" recommendations and are considered to be strong. A "must do" recommendation is usually a policy to comply with health and safety recommendations, such as hand washing; a "could do" recommendation is one that some patients may opt out of because other options are less effective but more acceptable. The National Institute for Health and Clinical Excellence describes "should do" and "should not do" recommendations as interventions that, in most people, will lead to more good than harm. 6 The second dimension describing the recommendation is the evidentiary base. C-CHANGE works with the guideline groups to ensure that the evidence cited and systematic reviews are of the highest quality and reviewed by experts in critical appraisal who have no competing interests. For drug and device recommendations, the highest level of evidence is required from randomized controlled trials of hard outcomes with adequate power and appropriate internal and external validity. 7 Health behaviour change and diagnostic recommendations can have evidence with surrogate outcomes. Every effort is made to reduce the number of recommendations that are based on consensus opinion only, but these are still considered strong recommendations, as most people would follow the expert opinion where sufficient evidence does not exist. Drug and device recommendations are not based on consensus opinion. C-CHANGE aims to select recommendations based on high-quality evidence and to minimize recommendations that are based on consensus (8 of the 76 recommendations [10.5%] are consensus).
Major changes in recommendations
Hypertension
The Systolic Blood Pressure Intervention Trial (SPRINT) study, published in November of 2015, has led to substantial changes in blood pressure measurement and management recommendations in Canada and the United States. 64, 65 After SPRINT's publication, a new category for hypertension for high-risk individuals was developed in Canada by Hypertension Canada with a new lower threshold for treatment (130 mm Hg systolic) and the lowest target blood pressure yet in any Canadian guideline (< 120 mm Hg systolic). This large National Institutes of Health study has excellent internal and external validity and showed that the lower blood pressure target offered a substantial cardiovascular benefit for higher-risk patients who had a systolic blood pressure of 130 mm Hg or more and the presence of a Framingham Risk Score of 15% or more, chronic kidney disease (estimated glomerular filtration rate [eGFR] 20-60 mL/min), or were aged 75 and older. The study did not include patients with diabetes or previous stroke, or those with postural hypotension, or who were unwilling to take intensified therapy. The results showed a relative risk reduction of cardiovascular events by 25% (95% confidence interval [CI] 0.64-0.89) and total mortality by 27% (95% CI 0.60-0.90) at only 3.3 years and associated numbers needed to treat of 62 and 90, respectively, over three years. 65 The number needed to treat of the primary outcome over 3.14 years for participants aged 75 and older was 27, and for frail compared with fit participants, there was greater absolute benefit. 66 The SPRINT study was also consistent with the recent Hypertension Canada change in recommendation on blood pressure measurement in the office. 11 Automated oscillometric devices are now preferred over manual readings with aneroid or mercury sphygmomanometers, and home measurements or, preferably, ambulatory blood pressure monitoring are recommended for the diagnosis of hypertension. 11, [67] [68] [69] [70] [71] [72] Measurement of blood pressure with automated devices in the waiting room and in the pharmacy has been shown to closely approximate home blood pressure monitoring, as well as daytime ambulatory blood pressure monitoring. 73 Single-pill combinations are now recommended as initial therapy for patients with elevated blood pressure even less than 20/10 above target. The evidence comes from the improved adherence and efficacy of single-pill combinations and studies showing a reduction in cardiovascular events. HC 19 We suggest that all individuals be encouraged to moderate energy (caloric) intake to achieve and maintain a healthy body weight and adopt a healthy dietary pattern to lower their risk of cardiovascular disease: 
Diabetes
People with diabetes should be offered timely self-management education that is tailored to enhancing self-care practices and behaviours.
DC 21
Overweight or obesity
A dietary plan for improving health for adults with obesity should be part of a weight-management strategy. Obesity
22
A comprehensive healthy lifestyle intervention is recommended for people with overweight and obesity. Obesity • Microvascular (retinopathy, neuropathy, nephropathy) • Cardiovascular (coronary, cerebrovascular, peripheral)
• Presence of vascular risk factors: Four approaches can be used to assess BP:
• AOBP is the preferred method of performing in-office BP measurement. When using AOBP, a displayed mean SBP ≥ 135 mm Hg or DBP ≥ 85 mm Hg is high.
• When using non-AOBP, a mean SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg is high, and an SBP between 130 and 139 mm Hg and/ or a DBP between 85 and 89 mm Hg is high-normal.
• Using ambulatory BP monitoring, patients can be diagnosed as hypertensive if the mean awake SBP is ≥ 135 mm Hg or the DBP is ≥ 85 mm Hg, or if the mean 24-hour SBP is ≥ 130 mm Hg or the DBP is ≥ 80 mm Hg.
• Using home BP monitoring, patients can be diagnosed as hypertensive if the mean SBP is ≥ 135 mm Hg or the DBP is ≥ 85 mm Hg. If the office BP measurement is high and the mean home BP is < 135/85 mm Hg, it is advisable to either repeat home monitoring to confirm the home BP is < 135/85 mm Hg or perform 24-hr ambulatory BP monitoring to confirm that the mean 24-hr ambulatory BP monitoring is < 130/80 mm Hg and the mean awake ambulatory BP monitoring is < 135/85 mm Hg before diagnosing white coat hypertension.
Dyslipidemia
For management of dyslipidemia, the Canadian approach is a treatto-target model. The Canadian Cardiovascular Society guideline for managing dyslipidemia in adults to prevent cardiovascular disease recommends pharmacologic therapy with statins for high-risk groups, including those with clinical atherosclerosis, abdominal aortic aneurysm, diabetes, chronic kidney disease, or low-density lipoprotein (LDL) cholesterol ≥ 5.0 mmol/L, as well as a Framingham Risk Score of ≥ 20%. However, for primary prevention, a risk assessment is required, as those with a risk score < 10% do not require pharmacotherapy, and a "fire-and-forget" strategy is inappropriate (i.e., treatment without follow-up blood tests to monitor lipid levels). Consider informing patients of their global risk to improve the effectiveness of risk factor modification. Consider also using analogies that describe comparative risk, such as "cardiovascular age," "vascular age," or "heart age" to inform patients of their risk status.
HC 28
Heart failure
We recommend that patients with known or suspected heart failure should be assessed for multimorbidity, frailty, cognitive impairment, dementia and depression, all of which may affect treatment, adherence to therapy, follow-up or prognosis.
HF 29
Hypertension
Global cardiovascular risk should be assessed. Multifactorial risk assessment models can be used to:
• Predict more accurately an individual's global cardiovascular risk • Help engage individuals in conversations about health behaviour change to lower BP • Use antihypertensive therapy more efficiently
In the absence of Canadian data to determine the accuracy of risk calculations, avoid using absolute levels of risk to support treatment decisions.
HC 30
Stroke
Persons at risk of stroke and patients who have had a stroke should be assessed for vascular disease risk factors, lifestyle management issues (diet, sodium intake, exercise, weight, alcohol intake, smoking) and use of oral contraceptives or hormone replacement therapy. Persons at risk of stroke should receive information and counselling about possible strategies to modify their lifestyle and risk factors. Referrals to appropriate specialists should be made where required. They may provide more comprehensive assessments and structured programs to manage specific risk factors. .) †Based on consensus opinion. ‡Men aged < 55 yr and women aged < 65 yr of age in first-degree relative. §Chronic kidney disease: eGFR < 60 mL/min/1.73 m 2 or ACR > 3 mg/mmol for at least 3-mo duration.
For those at intermediate risk, there is consideration of therapy based on other risk factors, such as an LDL ≥ 3.5, non-high-density lipoprotein (non-HDL) cholesterol ≥ 4.3, apolipoprotein B-100 ≥ 1.2, or men aged 50 years or older and women aged 60 years or older with one additional cardiovascular disease risk factor. These targets come from studies showing that achieving lower LDL levels was associated with better outcomes, 75 that the proportional reduction of major cardiovascular events was directly related to the 
Heart failure
We recommend that BNP/NT-proBNP levels be measured to help confirm or rule out a diagnosis of heart failure in the acute or ambulatory care setting in patients in whom the cause of dyspnea is in doubt. HF 32 We recommend that patients who receive potentially cardiotoxic cancer therapy undergo evaluation of LVEF before the start of cancer treatments known to cause impairment in LV function.
HF †
Hypertension
Routine laboratory tests that should be performed for the investigation of all patients with hypertension include the following:
• Urinalysis • Blood chemistry (potassium, sodium, and creatinine) • Fasting blood glucose or A 1C • Serum total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides; lipids may be drawn fasting or nonfasting • Standard 12-lead electrocardiography HC 34 Standardized office BP measurement should be used for follow-up. Measurement using electronic (oscillometric) upper arm devices is preferred over auscultation.
HC 25
In patients with large arm circumference when standard upper arm measurement methods cannot be used, validated wrist devices (used with arm and wrist supported at heart level) may be used for blood pressure estimation. 
All
We recommend that a cardiovascular risk assessment be completed every 5 yr for men and women aged 40 to 75 yr using the modified FRS or CLEM to guide therapy to reduce major cardiovascular events. A risk assessment might also be completed whenever a patient's expected risk status changes. CCS 34 We recommend calculating and discussing a patient's "cardiovascular age" to improve the likelihood that patients will reach lipid targets and that poorly controlled hypertension will be treated. We recommend sharing the results of the risk assessment with the patient to support shared decision-making and improve the likelihood that patients will reach lipid targets. In people with type 2 diabetes, an A 1C ≤ 6.5% may be targeted to reduce the risk of chronic kidney disease and retinopathy if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) used, and the person's characteristics. • Functionally dependent: 7.1%-8.0%
• History of recurrent severe hypoglycemia, especially if accompanied by hypoglycemia unawareness: 7.1%-8.5%
• Limited life expectancy: 7.1%-8.5%
• Frail, older age or with dementia: 7.1%-8.5%
• End of life: A 1C measurement not recommended. Avoid symptomatic hyperglycemia and any hypoglycemia.
DC †
An intensive healthy behaviour intervention program, combining dietary modification and increased physical activity, may be used to achieve weight loss, improve glycemic control and reduce CV risk.
DC 38
Dyslipidemia
We recommend a target LDL-C consistently < 2.0 mmol/L or > 50% reduction of LDL-C in individuals for whom treatment is begun, to decrease the risk of CVD events. Alternative target variables are apoB < 0.8 g/L or non-HDL-C < 2.6 mmol/L. CCS 39 We recommend a > 50% reduction of LDL-C for patients with LDL-C > 5.0 mmol/L in individuals for whom treatment is begun, to decrease the risk of CVD events and mortality.
CCS 39
Hypertension
For nonhypertensive individuals (to reduce the possibility of becoming hypertensive) or for hypertensive patients (to reduce their BP), prescribe the accumulation of 30-60 min of moderate intensity dynamic exercise (e.g., walking, jogging, cycling or swimming) 4-7 d/wk in addition to the routine activities of daily living.
HC †
For high-risk patients aged 50 yr or older, with SBP levels ≥ 130 mm Hg, intensive management to target an SBP of ≤ 120 mm Hg should be considered. Intensive management should be guided by AOBP measurements. Patient selection for intensive management is recommended and caution should be taken in certain high-risk groups. HC 40 Antihypertensive therapy should be prescribed for average DBP measurements of ≥ 100 mm Hg or average SBP measurements of ≥ 160 mm Hg in patients without macrovascular target organ damage or other cardiovascular risk factors. Antihypertensive therapy should be strongly considered for average DBP readings ≥ 90 mm Hg or for average SBP readings ≥ 140 mm Hg in the presence of macrovascular target organ damage or other independent cardiovascular risk factors. HC 41, 42 People with diabetes mellitus should be treated to attain SBP of < 130 mm Hg and DBP of < 80 mm Hg (these target BP levels are the same as BP treatment thresholds).
DC 43
Obesity
All those considering beginning a vigorous exercise program are encouraged to consult their physician or health care team professionals. absolute LDL reduction with no evidence of a threshold, 76 that better outcomes were seen with at least a 50% reduction in LDL, 77, 78 and that intensification of statin therapy was associated with better outcomes in patients with cardiovascular disease. 39, 79 The European Society of Cardiology 80 and the American College of Cardiology 81 have recommended the use of targets as well.
Diabetes
The assessment of diabetes now includes testing with a two-hour plasma glucose after a 75 g oral glucose tolerance test for people with glycosylated hemoglobin (A 1c ) levels from 6.0% to 6.4%. Reliance on A 1c or fasting plasma glucose alone can miss impaired fasting glucose or impaired glucose tolerance 82 and the oral In adults with type 2 diabetes with clinical CVD in whom glycemic targets are not achieved with existing antihyperglycemic medication, an antihyperglycemic agent with demonstrated CV outcome benefit (empagliflozin, liraglutide, canagliflozin) should be added to reduce the risk of major CV events.
• An SGLT2 inhibitor with demonstrated reduction in hospital admissions for heart failure may be added to reduce the risk of admission for heart failure.
DC [48] [49] [50] ACE inhibitor or ARB, at doses that have demonstrated vascular protection, should be used to reduce CV risk in adults with type 1 or type 2 diabetes with any of the following:
• Clinical CVD • Age ≥ 55 yr with an additional CV risk factor or end organ damage (albuminuria, retinopathy, left ventricular hypertrophy)
• Microvascular complications.
DC 51
Dyslipidemia
We recommend management that includes statin therapy in high-risk conditions including clinical atherosclerosis, abdominal aortic aneurysm, most DM, chronic kidney disease (age > 50 yr), and those with LDL-C ≥ 5.0 mmol/L to decrease the risk of CVD events and mortality. For individuals not at LDL-C goal despite statin therapy as described above, a combination of statin therapy with second-line agents may be used to achieve the goal; the agent used should be selected based upon the size of the existing gap to LDL-C goal.
CCS
DC †
We recommend management that includes statin therapy for individuals at high risk (modified FRS ≥ 20%) to decrease the risk of CVD events.
CCS 53 We recommend management that includes statin therapy for individuals at intermediate risk (modified FRS 10%-19%) with LDL-C ≥ 3.5 mmol/L to decrease the risk of CVD events. Statin therapy should also be considered for persons at intermediate risk with LDL-C < 3.5 mmol/L but with apoB ≥ 1.2 g/L or non-HDL-C ≥ 4.3 mmol/L, or in men aged ≥ 50 yr and women aged ≥ 60 yr with ≥ 1 CV risk factor.
CCS 54
Heart failure
We recommend that most patients with HFrEF be treated with triple therapy including an ACE inhibitor (or an ARB in those who are ACE -inhibitor intolerant), a beta blocker and an MRA unless specific contraindications exist.
HF 55 We recommend loop diuretics be used to control symptoms of congestion and peripheral edema. HF †
We suggest that NOACs should be the agent of choice for stroke prophylaxis in patients with HF and nonvalvular AF, and that the treatment dose be guided by patient-specific characteristics including age, weight and renal function.
HF 56 We recommend that an ARNI be used in place of an ACE inhibitor or ARB, in patients with HFrEF who remain symptomatic despite treatment with appropriate doses of GDMT to decrease cardiovascular death, hospital admissions for heart failure, and symptoms.
glucose tolerance test is of benefit in patients with unexplained microvascular complications. It also helps to identify those who will benefit from a reduction in cardiovascular risk factors. 83 Higher prevalence of hemoglobinopathies also reduce the accuracy of A 1c in high-risk non-Caucasian ethnic groups. 84 The management of type 2 diabetes has been expanded with two new medication classes, the sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists, with some members of each class showing reductions in major cardiovascular outcomes in addition to blood glucoselowering and, often, weight loss. 85 An antihyperglycemic agent with proven cardiovascular benefit should be added to existing therapy to reduce cardiovascular outcomes. 85 Addition of an SGLT2 inhibitor or a GLP-1 agonist is recommended for patients with uncontrolled diabetes and cardiovascular disease.
The current recommendation for an angiotensin-converting inhibitor or an angiotensin-receptor blocker in patients with diabetes is for patients older than 55 years who have one additional cardiovascular risk factor, or clinical cardiovascular disease or microvascular complications. This is a change from previous recommendations that all people with diabetes older than 55 years should be treated with a renin angiotensin-aldosterone system blocker, considering the lack of evidence for cardiovascular benefits in the lower-risk population.
Atrial fibrillation
The use of direct oral anticoagulants is recommended for nonvalvular atrial fibrillation over warfarin, based on randomized controlled trials showing equal or greater reduction of stroke, equal or less major bleeding, less intracranial bleeding, and no net increase in coronary artery disease outcomes. We recognize that as yet there are no long-term data on the effect of new oral anticoagulants on coronary outcomes, in contrast to that for efficacy of warfarin. • Recommended monotherapy choices are:
• A thiazide or thiazide-like diuretic, with longer-acting diuretics preferred, • A beta-blocker (in patients < 60 yr), • An ACE inhibitor (in patients who are not black), • An ARB, or • A long-acting CCB.
• Recommended choices for single-pill combinations are those in which an ACE inhibitor is combined with a CCB, ARB with a CCB, or ACE inhibitor or ARB with a diuretic.
• Hypokalemia should be avoided in patients treated with thiazide or thiazide-like diuretic monotherapy.
HC 58
Alpha-blockers are not recommended as first-line agents for uncomplicated hypertension; beta-blockers are not recommended as first-line therapy for uncomplicated hypertension in patients aged ≥ 60 yr; and ACE inhibitors are not recommended as first-line therapy for uncomplicated hypertension in black patients. However, these agents may be used in patients with certain comorbid conditions or in combination therapy. HC 59.60 For patients with stable angina pectoris but without prior heart failure, MI or coronary artery bypass surgery, either a beta-blocker or a CCB can be used as initial therapy. 
Health behaviours
Changes in recommendations regarding health behaviours include recognition that high sodium intakes (i.e., > 6 g/d) are associated with worse cardiovascular outcomes, particularly in people with hypertension. 87 Avoiding a diet high in sodium and aiming for a total daily sodium intake toward 2 g (5 g of salt or 87 mmol of sodium) per day is recommended to lower blood pressure in people with hypertension and to prevent or delay the new onset of hypertension in those at risk. 74 For dietary intake, maintaining sufficient calories for a healthy body weight and consuming a diet that is enjoyable and culturally appropriate is an overarching goal; when combined with regular physical activity, as outlined by the Canadian Society of Exercise Physiology guideline, diet can help to prevent type 2 diabetes. 88 Cigarette smoking is a well-established risk factor for vascular disease. There is now sufficient evidence for recommendations for screening and advising on smoking cessation, as well as the use of pharmacotherapy for smoking cessation. 89 Much of the evidence is summarized in a Cochrane collaboration systematic review finding that brief physician advice to stop smoking led to clinically important increases in smoking cessation, and advice combined with pharmacotherapy increased cessation rates over advice alone.
27,90
Implementation
Continuing professional development is an important method of disseminating guidelines to primary care practitioners. C-CHANGE's electronic continuing professional development modules are hosted on the College of Family Physicians of Canada's Prevention in Hand initiative website (www. preventioninhand .com /Modules.aspx), and are accredited by the college and the Royal College of Physicians and Surgeons of Canada. C-CHANGE education modules facilitate small-group, case-based practice workshops; each is codeveloped by a member of the College of Family Physicians of Canada.
C-CHANGE supports the development of implementation tools for provincial and regional applications by asking these groups to include a guideline developer as part of the process, to ensure that the adaptation is true to the original recommendation and able to receive C-CHANGE endorsement. 18 Patients often have multiple comorbidities, complicated by conditions such as stroke or myocardial infarction. A disease-silo approach to care leads to the risk of fragmentation, overlooking treatable risk factors. C-CHANGE helps to promote patient care by bringing guidelines from multiple groups together, formatted so that members of the interprofessional team can collaborate to formulate a comprehensive treatment plan directed to patient priorities. This makes it easier to achieve integration of primary and specialty care and to align this with the patient's health outcome goals and preferences. 91 The development of C-CHANGE guideline-based quality practice indicators, such as those in the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) study, 92 allow for surveillance and evaluation of primary care practice behaviours and can inform the guideline development process about practice gaps, or recommendations that may not be able to be implemented. Ongoing "real-world" surveillance of practice changes recommended by the C-CHANGE guideline is important to identify where "practice gaps" exist and where guideline implementation efforts are most needed. Use of the set of quality indicators developed by the CANHEART initiative (based on previous versions of the C-CHANGE guideline) has shown that health regions in Ontario with better adherence to these guidelines have fewer cardiovascular events. 92, 93 The Triple Aim Framework offers a foundation for health care providers to conceptualize health care with an emphasis on optimizing health for individuals and populations, and the health care experience. 94 This framework considers the patient experience of care, health of populations and per capita cost of health care, all of which need to be considered simultaneously. Leveraging the C-CHANGE harmonization of cardiovascular guidelines, the "real-world" surveillance of current practices and quality indicators and patient experiences, health care providers and decision-makers may assess, evaluate and identify opportunities for health care improvement across many patients with comorbidities, in alignment with this framework.
Telehealth interventions that include technologies (social networking services, smart phone applications, and patient and clinician portals) may enhance the remote delivery, support and monitoring of interventions reflective of C-CHANGE recommendations and quality indicators. 95 With respect to the importance of healthy behaviours in preventing and managing cardiovascular disease, technologies may provide patients with asynchronous or synchronous access to feedback from health care professionals, while giving health care practitioners insightful patient data on healthy behaviours, medication adherence and other health goals. Technology preferences should be tailored to meet the needs of the patient and provider, as well as being integrated with electronic medical records. 96, 97 The next update of the C-CHANGE guideline is projected to be in 2021, dependent on sufficient changes in the existing recommendations, or sooner if warranted by new evidence that will substantially change primary care practice. During this time, C-CHANGE will provide feedback to the individual guideline groups on their recommendations. Table 9 highlights some recommendations from other guidelines that differ from those included in this C-CHANGE update. 
Other guidelines
Gaps in knowledge
Obesity impairs health with respect to physical, mental and social well-being. We recommend the assessment and management of obesity using body mass index and waist circumference measurements as initial screening tools; however, these measures are based on Caucasians. Because body fat distribution varies with different ethnicity, different ethnicity-specific cutpoints for body mass index and waist circumference may provide more accurate assessment of adiposity-related complications in specific populations. 103 Other gaps include blood pressure measurement and treatment thresholds for home and ambulatory monitoring in people with diabetes, as well as the management of resistant hypertension.
Conclusion
The C-CHANGE Initiative has resulted in a comprehensive set of recommendations that provide a single national authoritative source for the primary care management of cardiovascular disease. C-CHANGE shows that Canada's national cardiovascular-focused guideline groups can produce rigorous harmonized recommendations that allow interprofessional teams to manage, collaboratively and confidently, Canadians who have and are at risk for cardiovascular disease. This set of recommendations can be implemented and disseminated to meet the regional needs of Canadians. Recommend in addition to metformin, adding the newer antihyperglycemic agents, including DPP4 inhibitor, SGLT2 inhibitor and GLP-1 RA, and all groups recommend an A 1c < 7.0 for most patients.
American College of Cardiology/American Heart Association Lipid guideline 100 Did not recommend a specific target but did advocate more intensive therapy or combination for those who did achieve a good response to statins (i.e., > 50% reduction).
European Society of Cardiology 101
Treat-to-target approach for lipid management, targeting an LDL-C < 1.8 mmol/L for very high-risk patients.
Note: A1C = glycosylated hemoglobin, BMI = body mass index, BP = blood pressure, BPM = blood pressure monitoring, CV = cardiovascular, DPP4 = dipeptidyl peptidase-4, GLP-1 RA = glucagon-like peptide-1 receptor agonists, LDL-C = low-density liproprotein cholesterol, SGLT2 = sodium-glucose cotransporter 2.
